Citigroup Inc Gilead Sciences, Inc. Call Options Transaction History

Citigroup Inc

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$66.59 - $83.99 $6.5 Million - $8.2 Million	-97,600 Reduced 25.67%	282,600 $23.7 Million
Q2 2024 Aug 12, 2024	BUY	$63.15 - $72.88 $10.6 Million - $12.3 Million	168,200 Added 79.34%	380,200 $26.1 Million
Q1 2024 May 10, 2024	BUY	$71.58 - $87.29 $85,896 - $104,748	1,200 Added 0.57%	212,000 $15.5 Million
Q4 2023 Feb 09, 2024	SELL	$73.27 - $83.09 $1.54 Million - $1.74 Million	-21,000 Reduced 9.06%	210,800 $17.1 Million
Q3 2023 Nov 09, 2023	BUY	$73.94 - $80.67 $5.23 Million - $5.71 Million	70,800 Added 43.98%	231,800 $17.4 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $1.52 Million - $1.73 Million	20,000 Added 14.18%	161,000 $12.4 Million
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $2.32 Million - $2.64 Million	30,000 Added 27.03%	141,000 $11.7 Million
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $26.3 Million - $37.7 Million	-421,700 Reduced 79.16%	111,000 $9.53 Million
Q3 2022 Nov 10, 2022	BUY	$59.54 - $68.01 $6.61 Million - $7.56 Million	111,100 Added 26.35%	532,700 $32.9 Million
Q2 2022 Aug 10, 2022	BUY	$57.72 - $65.01 $12.3 Million - $13.9 Million	213,400 Added 102.5%	421,600 $26.1 Million
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $77.4 Million - $96.9 Million	-1,335,500 Reduced 86.51%	208,200 $12.4 Million
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $2.27 Million - $2.58 Million	35,000 Added 2.32%	1,543,700 $112 Million
Q3 2021 Nov 10, 2021	BUY	$67.69 - $73.03 $102 Million - $110 Million	1,508,700 New	1,508,700 $105 Million

1,923

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.